FimmCyte Therapeutics
- Biotech or pharma, therapeutic R&D
FimmCyte is a Swiss biotech developing disease modifying therapies for treatment resistant fibrosis. Our differentiated pipeline is built on our proprietary principle of Deplete.Reprogram.Regenerate™. Our assets are engineered to simultaneously eliminate diseased cells and reprograms the micronevironment, leading to fibrosis reversal and organ regeneration. This revolutionary approach has significant potential in transforming chronic diseases such as kidney fibrosis, atherosclerosis, and endometriosis, from daily treatments to a few administrations per year.
We are seeking investors and pharma partnerships to advance these unique molecules to the clinic.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}